新诊断2型糖尿病患者应用利格列汀治疗对胰岛β细胞功能改善效果观察

Effect observation of Trajenta treatment on the improvement of islet β-cells function in patients with newly diagnosed type 2 diabetes mellitus

目的探析2型糖尿病患者应用利格列汀治疗对胰岛β细胞功能的改善效果。方法 80例2型糖尿病患者,随机分为对照组和观察组,每组40例。对照组患者口服格列吡嗪治疗,观察组患者口服利格列汀治疗。观察比较两组患者的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹C肽(FC-P)、餐后2 h C肽(2 h C-P)水平以及并发症发生情况。结果治疗前,两组患者的FPG、2 h PG、HbA1c、FC-P、2 h C-P水平比较差异无统计学意义(P>0.05);治疗后,两组患者的FPG、2 h PG、HbA1c、FC-P、2 h C-P水平均低于治疗前,且观察组患者的FPG、2 h PG、HbA1c、FC-P、2 h C-P水平均低于对照组,差异具有统计学意义(P<0.05)。对照组患者中12例发生不良反应,观察组患者中2例发生不良反应;观察组患者的不良反应发生率5.0%显著低于对照组的30.0%,差异具有统计学意义(P<0.05)。结论 2型糖尿病患者应用利格列汀治疗可以使患者胰岛β细胞功能改善,可以使患者糖尿病病情改善,值得临床推广。

Objective To investigate the improvement effect of Trajenta treatment on islet β-cell function in patients with newly diagnosed type 2 diabetes mellitus. Methods A total of 80 patients with type 2 diabetes mellitus were randomly divided into control group and observation group, 40 cases in each group. Patients in the control group were treated with Glipizide, patients in the observation group were taken Trajenta orally. The levels of fasting plasma glucose（FPG）, postprandial 2 h plasma glucose（2 h PG）, glycosylated hemoglobin（HbA1c）, fasting C peptide（FC-P）, postprandial 2 h C peptide（2 h C-P） and occurrence of complications between the two groups were observed and compared. Results Before treatment, there were no significant differences in the levels of FPG, 2 h PG, HbA1c, FC-P and 2 h C-P between the two groups（P〉0.05）. After treatment, the levels of FPG, 2 h PG, HbA1c, FC-P and 2 h C-P in the two groups were significantly lower than those before treatment, and the levels of FPG, 2 h PG, HbA1c, FC-P and 2 h C-P in the observation group were significantly lower than those in the control group, the differences were statistically significant（P〈0.05）. There were 12 cases of adverse reactions in the control group and 2 cases in the observation group. The incidence of adverse reactions in the observation group was 5.0%, which was significantly lower than 30.0% in the control group, the difference was statistically significant（P〈0.05）. Conclusion The application of Trajenta in the treatment of type 2 diabetes mellitus can improve the islet β-cells function and diabetic condition of patients, it is worthy of clinical promotion.